Clinical Trials on Pre-operative Anxiety in Czechia

Total 62 results

Stimvia s.r.o.

Completed

Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).

Overactive Bladder (OAB) | Failed Any OAB Pharmacotherapy

Czechia
St. Anne's University Hospital Brno, Czech Republic

Recruiting

Rest PETCO2 as a Predictor of Post-operative Complications

Post-Op Complication

Czechia
National Institute of Mental Health, Czech Republic

Completed

Virtual Reality Exposure Therapy for Acrophobia

Anxiety Disorders | Specific Phobia | Fear of Heights | Acrophobia

Czechia
National Institute of Mental Health, Czech Republic

Recruiting

Pregnancy Without Psychosocial Stress

Depression, Postpartum | Depressive Symptoms | Anxiety Disorders and Symptoms

Czechia
National Institute of Mental Health, Czech Republic

Recruiting

Kogito: App to Reduce Perinatal Psychosocial Stress

Depression, Anxiety | Psychological Stress | Perinatal Problems

Czechia
Vensica Therapeutics Ltd.

Completed

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

Overactive Bladder

Czechia, Portugal
General University Hospital, Prague
Charles University, Czech Republic; Institute of Hematology and Blood Transfusion...

Recruiting

Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia (PRIME)

Preterm Birth | Preeclampsia

Czechia
Charles University, Czech Republic

Unknown

AMAZING PRAGUE (PRAGUE-12) (AmP)

Atrial Fibrillation | Restore of Sinus Rhythm | Post-Operative Complications

Czech Republic
Charles University, Czech Republic

Unknown

On-Pump vs. Off-Pump CABG in High-Risk Patients (EuroSCORE 6+) (PRAGUE 6+)

Ischemic Heart Disease | Post-Operative Complications

Czech Republic
Sanofi

Completed

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder (ELECTRA)

Anxiety Disorders

Poland, Bulgaria, Serbia, Czech Republic, Croatia
Paion UK Ltd.
Chiltern International Ltd.; HFL Ltd.

Completed

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

Postoperative Pain

France, Germany, Netherlands, Poland, United Kingdom, Czechia
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. (GAD)

Generalized Anxiety Disorder

Guatemala, Spain, Italy, France, Czechia, Costa Rica, Mexico
Angelini Pharma Česká republika s.r.o.
National Institute of Mental Health (NIMH); Institut biostatistiky a analýz... and other collaborators

Terminated

First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)

Adult Patients | Major Depressive Disorder Co-Occurrent With Anxiety | Newly Diagnosed Depression

Czechia
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

Costa Rica, Austria, Croatia, India, Serbia, Mexico, Russian Federation, Finland, Lithuania, Greece, Czechia, Indonesia, Argentina, Slovenia, Spain, Turkey
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

Generalized Anxiety Disorder

United States, Serbia, Hungary, Russian Federation, Finland, Ukraine, Estonia, Czechia
Masaryk University

Completed

Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring

Preeclampsia

Czech Republic
Allergan

Completed

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Belgium, Canada, Russian Federation, United States, Germany, Czechia
Allergan

Completed

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Germany, Canada, Belgium, United States, Czechia
Baxter Healthcare Corporation
Baxter Innovations GmbH

Completed

Oxidized Cellulose hEmostAsis evaluatioN (OCEAN)

Intra-operative Bleeding

Czech Republic, Germany, Hungary, Poland
AstraZeneca

Completed

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder (SILVER)

Generalized Anxiety Disorder

Sweden, Bulgaria, Czech Republic, France, Mexico, South Africa, Spain, Germany, Romania, Finland, Norway, Argentina, Canada, Denmark, Slovakia
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Sanofi

Completed

SSR240600C Treatment in Women With Overactive Bladder (BILADY)

Overactive Bladder

France, Germany, Netherlands, Portugal, Czech Republic, United States, Canada
Allergan

Completed

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder

Poland, United Kingdom, Belgium, Russian Federation, Czech Republic, Germany, United States
Ipsen

Terminated

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Overactive Bladder

United Kingdom, Spain, Netherlands, Belgium, France, Germany, Czechia, Italy
Bayer

Completed

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) (OVADER)

Overactive Bladder

Austria, Singapore, New Zealand, Australia, Portugal, Czechia, Poland, Germany, Sweden
Technische Universität Dresden

Completed

Psychiatric Day Hospital Treatment

Personality Disorders | Schizophrenia | Anxiety Disorders | Adjustment Disorders | Depressive Disorders

Czech Republic, Germany, Poland, Slovakia, United Kingdom
Pfizer

Completed

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

Overactive Bladder

Czech Republic, Slovakia, United Kingdom, Sweden, Norway, Lithuania
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
Allergan

Terminated

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Urinary Incontinence | Urinary Bladder | Overactive

United States, Australia, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, South Africa, United Kingdom
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

United Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Astellas Pharma s.r.o.

Completed

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Post-operative Peripheral Neuropathic Pain

Czech Republic
Pfizer

Completed

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Overactive Bladder

Costa Rica, United States, Korea, Republic of, Germany, Slovakia, Ukraine, Belgium, Poland, Czechia
Żelazna Medical Centre, LLC
Charles University, Czech Republic; Karolinska Institutet; Charite University... and other collaborators

Unknown

Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic (MindCOVID)

Depression | Anxiety | Pregnancy Related

Lebanon, Hong Kong, United States, Sweden, Germany, Australia, Poland, Italy, Taiwan, Albania, Czechia, France, Israel, Norway, Spain
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8539 in Patients With Overactive Bladder

Overactive Bladder

Poland, Ukraine, Romania, Russian Federation, Czech Republic, Hungary, Netherlands, Sweden, Germany
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania
Fundació Institut de Recerca de l'Hospital de la...
Fundacion Clinic per a la Recerca Biomédica

Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. (PE37)

Preeclampsia | Intrauterine Growth Restriction | Perinatal Death | Maternal Hypertension | Neonatal Outcome

Spain, Belgium, Czechia, Poland, India
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PLUS)

Overactive Bladder | Benign Prostatic Hyperplasia

United States, Canada, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Novartis Pharmaceuticals

Terminated

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Patient Diagnosed With OCD and Resistant to SSRI Treatment | Failed SSRI Over 12 Weeks at Appropriate Doses

Germany, Switzerland, Bulgaria, United States, Czech Republic
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (VEST)

Urinary Bladder, Overactive

Czech Republic

Clinical Trials on Pre-operative Anxiety in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations